Delving into the Latest Updates on HEC122505MsOH with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms-

Target

MAO-B

Mechanism

MAO-B inhibitors(Monoamine oxidase B inhibitors)

Therapeutic Areas

Nervous System DiseasesEndocrinology and Metabolic Disease

Active Indication-

Inactive Indication

Parkinson Disease

Originator Organization

Sunshine Lake Pharma Co., Ltd.

Active Organization-

Inactive Organization

Sunshine Lake Pharma Co., Ltd.

Drug Highest PhasePendingPhase 1

First Approval Date-

Regulation-

Login to view timeline

[Translation] A single-center, randomized, double-blind, placebo-controlled, dose-escalation safety, tolerability, and pharmacokinetic trial of single/multiple oral administration of HEC122505MsOH tablets and a single-center, randomized, double-blind, two-period crossover food effect trial in healthy Chinese subjects

评价HEC122505MsOH片在中国健康受试者中单次/多次口服给药的安全性、耐受性及药代动力学特征；评价食物对 HEC122505MsOH片药代动力学的影响。

[Translation]

To evaluate the safety, tolerability and pharmacokinetic characteristics of single/multiple oral administration of HEC122505MsOH tablets in healthy Chinese subjects; To evaluate the effect of food on the pharmacokinetics of HEC122505MsOH tablets.

Start Date20 Jan 2021

Sponsor / Collaborator

Sunshine Lake Pharma Co., Ltd.

100 Clinical Results associated with HEC122505MsOH

Login to view more data

100 Translational Medicine associated with HEC122505MsOH

Login to view more data

100 Patents (Medical) associated with HEC122505MsOH

Login to view more data

100 Deals associated with HEC122505MsOH

Login to view more data